GlaxoSmithKline'ın genel merkezi İngiltere'dedir. Şirket merkez bürosu Middlesex bölgesinin Brentford şehrinde, yeni binasında yer almaktadır. Dünya ilaç pazarının tahmini olarak %6.9'unu elinde bulunduran GlaxoSmithKline (GSK) dört ana terapötik alanda lider konumundadır: anti-infektifler, merkezi sinir sistemi, solunum sistemi ve gastro-enteroloji. GSK, bunlara ek olarak, giderek daha fazla önem kazanmakta olan aşı alanında ve gelişmekte olan onkoloji ürünlerinde de lider konuma gelmiştir.

GlaxoSmithKline'ın portföyünde bulunan elden reçetesiz satılan ilaçlar (OTC), besleyici içecekler ve ağız sağlığı ürünleri de pazarda lider konumdadır.
Şirketin pazar payı yüksek ürünleri arasında analjezikler, nikotin replasmanları, gastro-entestinal ve solunum ilaçları, beslenme ve dermatoloji ürünleri yer almaktadır. GSK ürünleri bugün 140 ülkede kullanılmaktadır.

İlaç sektöründe dünyanın en büyük satış ve pazarlama operasyonlarından birine sahip olan GSK'nın, tüm dünyada yaklaşık 40.000 kişiden oluşan bir satış ve pazarlama ekibi bulunmaktadır. Dünya çapında 41 ülkede, 108 üretim tesisinde, yaklaşık 39.000 kişi, Araştırma & Geliştirme bölümünde de 16.000 kişi çalışmaktadır Şirketin dünya çapında toplam çalışan sayısı ise 100.000'den fazladır.

TORONTO, Ontario (Tuesday, April 16, 2002) -- The D2/D3 dopamine agonist ReQuip® (ropinirole) significantly slows the loss of dopamine function when compared to the older generation treatment for Parkinson’s Disease levodopa (L-dopa), according to the results of the important new REAL-PET study1, announced today at the Annual Meeting of the American Academy of Neurology (AAN) in Denver, Colorado.

This study provides clear evidence that ReQuip slows the loss of dopamine function in the brain when compared to traditional treatment with L-dopa. Loss of dopamine function is a key indicator, or surrogate marker, of Parkinson’s Disease progression.

“The results of this study are very exciting. ReQuip has been shown to slow the progression of dopamine dysfunction associated with Parkinson’s Disease. This was demonstrated in both the striatum and the basal ganglia,” commented Professor David Brooks, lead investigator and Hartnett Professor of Neurology at the Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, UK. “These results should certainly stimulate debate about the way we treat early Parkinson’s Disease.”

The REAL-PET (ReQuip as Early Therapy versus L-dopa – PET) study is a multicentre, double-blind, parallel-group trial using a state-of-the-art computer brain imaging technique called three-dimensional positron emission tomography (3D PET), specifically designed to evaluate changes in 18F-dopa uptake (a surrogate marker for the quantity of functioning dopaminergic brain cells). The study randomised 186 early Parkinson’s Disease patients in a 1:1 ratio for two years of treatment with either ReQuip or L-dopa.

TORONTO, Ontario (September 30, 2002) -- Once-daily suppressive therapy with Valtrex® (valacyclovir hydrochloride) caplets reduced transmission of symptomatic genital herpes (genital herpes with active symptoms) by 77 per cent versus the placebo group, according to data presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) annual meeting. In addition, suppressive therapy reduced the overall transmission of the virus that causes genital herpes by 50 per cent. bu  bir  deneme

Valtrex is the only product that has been studied for the reduction of the transmission of genital herpes in heterosexual monogamous couples, and is currently indicated by Health Canada for the suppression of genital herpes outbreaks.

“Suppression with valacyclovir 500 mg once daily provides a brand new tool in herpes transmission prevention,” said Dr. Stephen Sacks, infectious disease physician and professor of Pharmacology and Therapeutics at the University of British Columbia. “People with genital herpes will want to have an honest herpes discussion with their sexual partner, consider a type-specific blood test for the partner to determine if he or she is susceptible, and use, as we recommended in this study, safer sex as the third principle in prevention. Suppressive therapy adds a novel fourth tool which is very effective.” Dr. Sacks went on to caution, “Even with all of these prevention tools in place, it remains possible to transmit genital herpes to a susceptible partner, but valacyclovir suppression significantly reduces the overall risk.”